Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells.
emulsion solvent evaporation technique
hepatocellular carcinoma
microfluidics
optical fiber
poly(lactic-co-glycolic acid)
sorafenib
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2023
accepted:
29
06
2023
medline:
3
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
Currently, conventional treatments of hepatocellular carcinoma (HCC) are not selective enough for tumor tissue and lead to multidrug resistance and drug toxicity. Although sorafenib (SOR) is the standard first-line systemic therapy approved for the clinical treatment of HCC, its poor aqueous solubility and rapid clearance result in low absorption efficiency and severely limit its use for local treatment. Herein, we present the synthesis of biodegradable polymeric Poly (D, L-Lactide-co-glycolide) (PLGA) particles loaded with SOR (PS) by emulsion-solvent evaporation process. The particles are carefully characterized focusing on particle size, surface charge, morphology, drug loading content, encapsulation efficiency, in vitro stability, drug release behaviour and tested on HepG2 cells. Additionally, PLGA particles have been coupled on side emitting optical fibers ( PS have a size of 248 nm, tunable surface charge and a uniform and spherical shape without aggregation. PS shows encapsulation efficiency of 89.7% and the highest drug loading (8.9%) between the SOR-loaded PLGA formulations. Treating HepG2 cells with PS containing SOR at 7.5 µM their viability is dampened to 40%, 30% and 17% after 48, 129 and 168 hours of incubation, respectively. The high PS stability, their sustained release profile and the rapid cellular uptake corroborate the enhanced cytotoxicity effect on HepG2. With the prospect of developing biomedical tools to control the spatial and temporal release of drugs, we successfully demonstrated the potentiality of
Identifiants
pubmed: 37525693
doi: 10.2147/IJN.S415968
pii: 415968
pmc: PMC10387258
doi:
Substances chimiques
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Sorafenib
9ZOQ3TZI87
Lactic Acid
33X04XA5AT
Polyglycolic Acid
26009-03-0
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4121-4142Informations de copyright
© 2023 Caputo et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
Curr Pharm Biotechnol. 2022;23(9):1214-1225
pubmed: 34445947
Gastroenterology. 2022 Mar;162(3):920-934
pubmed: 35210014
Opt Express. 2017 Oct 2;25(20):24521-24530
pubmed: 29041396
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Drug Deliv. 2021 Dec;28(1):1397-1418
pubmed: 34184949
Int J Pharm. 2017 Aug 7;528(1-2):88-99
pubmed: 28533175
Anticancer Agents Med Chem. 2018 Feb 07;17(14):1884-1897
pubmed: 28707574
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74
pubmed: 17160391
Drug Deliv. 2016 May;23(4):1398-403
pubmed: 26079530
Science. 1994 Mar 18;263(5153):1600-3
pubmed: 8128245
Nat Photonics. 2011 Oct 1;5(10):591-597
pubmed: 22059090
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Pharm Sci. 2015 Mar;104(3):1187-96
pubmed: 25573425
Int J Nanomedicine. 2011;6:1415-27
pubmed: 21796244
Nanomaterials (Basel). 2017 Jul 22;7(7):
pubmed: 28737672
Mol Pharm. 2019 Jan 7;16(1):1-23
pubmed: 30452861
Chem Soc Rev. 2022 Jul 4;51(13):5365-5451
pubmed: 35642539
J Pharm Biomed Anal. 2009 May 1;49(4):1109-14
pubmed: 19278805
Opt Express. 2019 Nov 11;27(23):34011-34021
pubmed: 31878458
Theranostics. 2021 Mar 13;11(11):5464-5490
pubmed: 33859758
J Cell Physiol. 2018 Jan;234(1):298-319
pubmed: 30078182
Nanomedicine (Lond). 2010 Jun;5(4):597-615
pubmed: 20528455
Cancer Res. 2006 Dec 15;66(24):11851-8
pubmed: 17178882
Acta Pharmacol Sin. 2015 Feb;36(2):241-51
pubmed: 25557114
J Clin Exp Hepatol. 2019 Sep-Oct;9(5):588-596
pubmed: 31695249
Pharmaceutics. 2019 Sep 23;11(10):
pubmed: 31548500
Nanomaterials (Basel). 2019 Oct 08;9(10):
pubmed: 31597260
Drug Deliv. 2022 Dec;29(1):342-350
pubmed: 35049388
ACS Appl Bio Mater. 2022 Mar 21;5(3):971-1012
pubmed: 35226465
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Acta Biomater. 2020 Jan 15;102:13-34
pubmed: 31759124
Med Oncol. 2017 Nov 9;34(12):195
pubmed: 29124473
Nanomedicine (Lond). 2014 Jan;9(1):121-34
pubmed: 24354814
Mol Imaging Biol. 2016 Dec;18(6):898-904
pubmed: 27172938
Colloids Surf B Biointerfaces. 2022 Feb;210:112254
pubmed: 34896692
J Hepatol. 2008 Nov;49(5):871-3
pubmed: 18817997
Dalton Trans. 2017 Nov 7;46(43):14746-14751
pubmed: 29034940
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Sci Adv. 2020 Jan 15;6(3):eaax3931
pubmed: 31998833
Drug Deliv. 2017;24(sup1):94-107
pubmed: 29124979
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):2978-83
pubmed: 25713374
Nanoscale Res Lett. 2012 Jan 27;7(1):91
pubmed: 22283905
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
ACS Nano. 2022 Jan 25;16(1):910-920
pubmed: 35023718
Polymers (Basel). 2018 Aug 09;10(8):
pubmed: 30960820
Small. 2017 Jan;13(2):
pubmed: 27735129
Nanomedicine (Lond). 2017 Feb;12(4):295-315
pubmed: 28093940
Trends Mol Med. 2015 Apr;21(4):223-32
pubmed: 25656384
Mater Sci Eng C Mater Biol Appl. 2016 May;62:927-42
pubmed: 26952500
Biomater Adv. 2022 Jun;137:212851
pubmed: 35929279
Biomaterials. 2014 May;35(15):4565-72
pubmed: 24602567
J Pharm Anal. 2023 Mar;13(3):239-254
pubmed: 37102112
RSC Adv. 2020 Jan 27;10(8):4218-4231
pubmed: 35495261
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
J Adv Res. 2023 Jan;43:87-96
pubmed: 36585117
Nanomedicine. 2016 Jul;12(5):1303-11
pubmed: 26964482
Acta Pharmacol Sin. 2017 May;38(5):614-622
pubmed: 28344323
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 29171928
Nanoscale. 2014 Mar 21;6(6):3231-42
pubmed: 24500240
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Opt Express. 2020 Aug 31;28(18):27028-27036
pubmed: 32906964
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
Sensors (Basel). 2018 Jun 30;18(7):
pubmed: 29966343
Lancet. 2003 Dec 6;362(9399):1907-17
pubmed: 14667750
Colloids Surf B Biointerfaces. 2016 Sep 1;145:392-400
pubmed: 27232302
ACS Appl Mater Interfaces. 2018 Apr 4;10(13):10664-10677
pubmed: 29508612
J Control Release. 2022 Jan;341:95-117
pubmed: 34774891
Ann Oncol. 2013 Dec;24(12):2952-62
pubmed: 23965736
AAPS J. 2021 Jun 29;23(4):92
pubmed: 34189655
Nanomedicine. 2014 Nov;10(8):1649-59
pubmed: 24905399
Appl Opt. 2011 Jun 10;50(17):2738-43
pubmed: 21673779